The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment

Author： Phillips C.J.  

Publisher： Adis International

ISSN： 1172-7047

Source： CNS Drugs, Vol.18, Iss.9, 2004-01, pp. : 561-574

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Analysis of Relapsing-Remitting Multiple Sclerosis in Italy after the Introduction of New Disease-Modifying Agents

By Russo P.  

Clinical Drug Investigation, Vol. 24, Iss. 7, 2004-01 ,pp. : 409-420

Adis International

Access to resources Recommend Favorite

Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 8, Iss. 6, 2009-12 ,pp. : 512-519

Bentham Science Publishers

Access to resources Recommend Favorite

Cost-Effectiveness Analyses of Natalizumab (Tysabri ® ) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

By Gani Ray  

PharmacoEconomics, Vol. 26, Iss. 7, 2008-01 ,pp. : 617-627

Adis International

Access to resources Recommend Favorite

Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis

By Nurmohamed Michael T.   Dijkmans Ben A.C.  

Drugs, Vol. 65, Iss. 5, 2005-01 ,pp. : 661-694

Adis International

Access to resources Recommend Favorite

Disease-Modifying Agents for Multiple Sclerosis: Recent Advances and Future Prospects

By Menge Til  

Drugs, Vol. 68, Iss. 17, 2008-01 ,pp. : 2445-2468

Adis International

Access to resources Recommend Favorite